Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Likangrui Bioengineering is a biotechnology company based in Shanghai, China, that focuses on the research, development, and production of plant-derived recombinant proteins. The company utilizes a specialized rice endosperm-specific expression platform to produce animal-free recombinant human serum albumin (OsrHSA) and other high-value proteins. These products are used as pharmaceutical excipients, cell culture media components, and are being advanced through clinical trials for therapeutic indications such as hypoproteinemia. Likangrui operates out of the Zhangjiang Hi-Tech Park and is a key player in the field of molecular farming and sustainable biomanufacturing. By leveraging plant-based systems, the company aims to provide a safer and more scalable alternative to plasma-derived or animal-derived proteins.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Likangrui Bioengineering.